Quarterly Result29 Jul 2026, 09:00 pm
Piramal Pharma Q1 FY27 Revenue Up 17% to ₹2,270 Cr, EBITDA Surges 72%
AI Summary
Piramal Pharma Limited announced its Q1 FY27 results, reporting a 17% year-on-year increase in consolidated revenue from operations to ₹2,270 Crores. EBITDA saw a significant surge of 72% to ₹285 Crores, with EBITDA margins expanding by 400 basis points to 12.5%. This growth was driven by strong performance across all three business segments: CDMO, Complex Hospital Generics (CHG), and Consumer Healthcare (PCH). The company highlighted improved operating leverage, capacity utilization, and pricing discipline as key factors for margin expansion. The Sellersville facility in the US also received a positive Establishment Inspection Report from the US FDA.
Key Highlights
- Consolidated revenue grew 17% YoY to ₹2,270 Cr in Q1 FY27.
- EBITDA increased 72% YoY to ₹285 Cr, with margins expanding to 12.5%.
- All three businesses (CDMO, CHG, PCH) delivered strong revenue growth.
- US FDA inspection of Sellersville facility concluded successfully with an EIR.
- CDMO business saw broad-based growth and inaugurated commercial-scale payload-linker suite.
Price Impact
More from PPLPHARMA